These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 37457534)
1. A prospective study to estimate the incidence and pattern of adverse drug reactions to first-line antiretroviral therapy (tenofovir, efavirenz, and lamivudine). Singh B; Guliani A; Hanumanthu V; Narang T; Dogra S; Handa S; Sharma A Indian J Sex Transm Dis AIDS; 2023; 44(1):6-10. PubMed ID: 37457534 [TBL] [Abstract][Full Text] [Related]
2. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK; N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults. Avihingsanon A; Maek-A-Nantawat W; Gatechompol S; Sapsirisavat V; Thiansanguankul W; Sophonphan J; Thammajaruk N; Ubolyam S; Burger DM; Ruxrungtham K Int J Infect Dis; 2017 Aug; 61():89-96. PubMed ID: 28627427 [TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
5. COMPARISON OF THAI GOVERNMENT MANUFACTURED TENOFOVIR (TENOFOVIR GPO300) WITH PRIVATELY MANUFACTURED TENOFOVIR (VIREAD) USED ALONG WITH LAMIVUDINE AND EFAVIRENZ TO TREAT THAI HIV PATIENTS. Manosuthi W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S Southeast Asian J Trop Med Public Health; 2015 Jan; 46(1):19-26. PubMed ID: 26513901 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibitor-containing first-line antiretroviral therapy in Pune, India. Dravid A; Betha TP; Sharma AK; Gawali R; Mahajan U; Kulkarni M; Saraf C; Kore S; Dravid M; Rathod N HIV Med; 2020 Oct; 21(9):578-587. PubMed ID: 33021066 [TBL] [Abstract][Full Text] [Related]
7. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Daar ES; Tierney C; Fischl MA; Sax PE; Mollan K; Budhathoki C; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Pappa KA; Woodward WC; Patterson K; Bolivar H; Benson CA; Collier AC; Ann Intern Med; 2011 Apr; 154(7):445-56. PubMed ID: 21320923 [TBL] [Abstract][Full Text] [Related]
8. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients. Manfredi R; Calza L AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748 [TBL] [Abstract][Full Text] [Related]
9. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Sturt AS; Dokubo EK; Sint TT Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370 [TBL] [Abstract][Full Text] [Related]
10. Could a Dolutegravir-Based Antiretroviral Therapy Lead to Clinical Obesity? A Retrospective Cohort Study Conducted at Hawassa University Comprehensive Specialized Hospital in Hawassa, Sidama, Ethiopia. Eifa BA; Ketema W AIDS Res Treat; 2022; 2022():2965325. PubMed ID: 35603131 [TBL] [Abstract][Full Text] [Related]
11. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240 [TBL] [Abstract][Full Text] [Related]
12. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Cvetkovic RS; Goa KL Drugs; 2003; 63(8):769-802. PubMed ID: 12662125 [TBL] [Abstract][Full Text] [Related]
13. WITHDRAWN. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV. Omeje I; Okwundu CI Cochrane Database Syst Rev; 2012 Feb; (2):CD007276. PubMed ID: 22336829 [TBL] [Abstract][Full Text] [Related]